The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: A multicenter study

Basit Öğe Kaydı
dc.authorid0000-0001-7934-7039
dc.authorid0000-0003-2715-4002
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorUncu, Doğan
dc.contributor.authorİnanç, Mevlüde
dc.contributor.authorKaya, Serap
dc.contributor.authorDane, Faysal
dc.contributor.authorKüçüköner, Mehmet
dc.contributor.authorDemirci, Ayşe
dc.contributor.authorBilici, Mehmet
dc.contributor.authorGök Durnalı, Ayşe
dc.contributor.authorKoral, Lokman
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorErol, Cihan
dc.contributor.authorTürkmen, Esma
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorAçıkgöz, Özgür
dc.contributor.authorLaçin, Şahin
dc.contributor.authorŞahinli, Hayriye
dc.contributor.authorUrakçı, Zuhat
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.date.accessioned2021-10-20T11:28:21Z
dc.date.available2021-10-20T11:28:21Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose We aim to compare the efficiency and toxicity of three different 5-fluorouracil (5-FU) administration types in 5-FU, leucovorin, and oxaliplatin (FOLFOX) combination treatment for adjuvant therapy in colorectal cancer (CRC). Methods Five hundred and seventy patients with stage III colorectal carcinoma who received different FOLFOX regimens after curative resection were included. Patients were divided into three groups as FOLFOX-4, modified FOLFOX-6 (mFOLFOX-6), and mFOLFOX-4 for comparison of toxicity and disease-free survival (DFS) and overall survival (OS) times. Results Three-year DFS rates for FOLFOX-4, mFOLFOX-6, and mFOLFOX-4 groups were 65%, 72%, and 72%, respectively. Five-year OS rates for FOLFOX-4, mFOLFOX-6, and mFOLFOX-4 groups were 69%, 75%, and 67%, respectively. There was no statistically significant difference between the three treatment groups in terms of DFS and OS (p = 0.079, and p = 0.147, respectively). Among grade 1-2 adverse events (AE), thrombocytopenia, neuropathy, and stomatitis were more common in the mFOLFOX-6-treated group. The frequency of grade 1-2 nausea and vomiting were similar in mFOLFOX-6 (36.3% and 24%, respectively) and mFOLFOX-4 (32.4% and 24.7%, respectively) groups but were higher than that in the FOLFOX-4 (19.5% and 11.3%, respectively) group. Among the most common grade 3-4 AE, neutropenia (53.4%, 9%, and 13.5%, respectively) and diarrhea (10.5%, 2.2%, and 2.4, respectively) were more common in FOLFOX-4. The rate of anemia and febrile neutropenia was similar in treatment groups (p = 0.063, and p = 0.210, respectively). Conclusion In the adjuvant treatment of stage III CRC patients, three different 5-FU administration types in FOLFOX combination treatment can be used with similar efficiency and manageable toxicity.
dc.identifier.citationAkdeniz, N., Kaplan, M. A., Uncu, D., İnanç, M., Kaya, S., Dane, F. ... Işıkdoğan, A. (2021). The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: A multicenter study. International Journal of Colorectal Disease, 36(6), 1311-1319. https://dx.doi.org/10.1007/s00384-021-03888-9
dc.identifier.doi10.1007/s00384-021-03888-9
dc.identifier.endpage1319
dc.identifier.issn0179-1958
dc.identifier.issn1432-1262
dc.identifier.issue6
dc.identifier.scopusqualityQ2
dc.identifier.startpage1311
dc.identifier.urihttps://dx.doi.org/10.1007/s00384-021-03888-9
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8488
dc.identifier.volume36
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofInternational Journal of Colorectal Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectAdjuvant Chemotherapy
dc.subjectColorectal Cancer
dc.subjectFOLFOX Regimens
dc.subjectStage III
dc.titleThe comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: A multicenter study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Olmez-Omer-2021.pdf
Boyut:
505.57 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu